SRC-1 Degrading PROTAC via N-degron Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PROTAC technology has limitations in targeting specific cells and tissues due to the restricted expression of E3 ubiquitin ligases, and existing SRC-1 inhibitors lack selectivity and high activity, making it difficult to effectively degrade SRC-1 protein for treating cancers and immune-related diseases.
Innovation Solution
A chimeric compound linking a ubiquitin ligase binding moiety to a steroid receptor coactivator-1 (SRC-1) binding moiety via a linker, utilizing the N-degron pathway to selectively degrade SRC-1 through the UBR E3 ubiquitin ligase family, overcoming tissue specificity and inhibitor limitations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional PROTAC technology uses limited E3 ubiquitin ligases (CRBN, VHL), then the structure and mechanism are well-established, but the types of cells and tissues that can be targeted are limited due to restricted E3 ligase expression
Solution Approach 1:
The patent applies universality by designing PROTAC molecules that can target multiple E3 ligase families (VHL, CRBN, Cereblon, and other Cullin-based E3 ligases) through a unified molecular framework. The chimeric compound structure allows binding to different E3 ligases while maintaining the core PROTAC mechanism, thereby expanding cell and tissue targeting capability across diverse expression patterns without requiring separate development for each E3 ligase type.
Solution Approach 2:
The patent employs parameter changes by systematically varying the E3 ligase binding domain within the PROTAC molecule to match different E3 ligase expression patterns in various cells and tissues. By adjusting which E3 ligase the PROTAC targets, the molecule can be optimized for specific tissue types, thereby expanding adaptability while managing the complexity through structured molecular design.
2Reliability
If existing SRC-1 inhibitors are developed, then they can potentially regulate SRC-1 transcriptional activity, but they have very low activity or no selectivity for SRC-1 due to the difficulty of targeting protein-protein interactions
Solution Approach 1:
The patent applies segmentation by dividing the SRC-1 inhibition task into two distinct functional modules: an SRC-1 binding ligand and an E3 ligase binding ligand, connected by a linker. This segmentation transforms the difficult single-step protein-protein interaction targeting into a two-component system where each module can be independently optimized for its specific binding target, thereby improving both selectivity and activity while simplifying the development process.
Solution Approach 2:
The patent uses an intermediary approach by introducing the E3 ligase as a mediator in the SRC-1 degradation process. Instead of directly inhibiting SRC-1 protein-protein interactions, the PROTAC molecule recruits E3 ligase to mediate the degradation of SRC-1 through the ubiquitin-proteasome pathway. This intermediary mechanism bypasses the difficulty of direct PPI targeting and achieves high efficacy and selectivity.
3Adaptability or versatility
If PROTAC molecules are designed to bind multiple E3 ligases, then the versatility increases, but the molecular complexity and design difficulty increase
Solution Approach 1:
The patent achieves universality by creating a PROTAC platform that can function with multiple E3 ligase types through a consistent molecular architecture. The chimeric compound design allows the same basic structure to bind different E3 ligases by varying the specific binding domain, providing a universal solution that reduces design complexity while maintaining broad versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound specifically binds to and degrades SRC-1, effectively treating immune-related diseases and cancers by targeting SRC-1 overexpression, demonstrating enhanced selectivity and activity compared to conventional inhibitors.
Implementation Method 1
The PROTAC binds to both proteins simultaneously, bringing the target protein into close proximity to the E3 ligase
Implementation Method 2
the E3 ligase recognizes the target protein as a substrate, resulting in polyubiquitination and subsequent proteasomal degradation
Implementation Method 3
resulting in polyubiquitination and subsequent proteasomal degradation
Implementation Method 4
The N-terminal amino acids of the substrate protein are recognized by the UBR E3 ubiquitin ligase family, and the substrate protein undergoes ubiquitination and degradation by the proteasome
Data Source
AI summary
The present invention relates to a novel class of a chimeric molecule associated with a chimeric compound design for degrading a desired target protein, SRC-1. More specifically, the present invention relates to a peptide compound for degrading SRC-1 protein, and a pharmaceutical composition for preventing or treating cancer metastasis and occurrence caused by SRC-1 overexpression, and for preventing or treating immune-related diseases.